Dose modification for haematological toxicity: a survey of Australian medical oncologists
| Autor: | Jeremy Shapiro, Brian Stein, Phillipa Smith, Christos S. Karapetis, Craig R. Lewis, Liesel Byrne, Lisa King, Aisling Kelly, Wanyuan Cui, Julia Shingleton, Rachel Wong |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncologists
medicine.medical_specialty Palliative treatment business.industry Australia Delayed treatment 030204 cardiovascular system & hematology Neutropenia Medical Oncology medicine.disease Clinical trial 03 medical and health sciences 0302 clinical medicine Clinical Protocols Surveys and Questionnaires Haematological toxicity Internal medicine Internal Medicine medicine Absolute neutrophil count Humans 030212 general & internal medicine business Adverse effect Dose Modification |
| Zdroj: | Internal Medicine Journal. 50:1338-1343 |
| ISSN: | 1445-5994 1444-0903 |
| DOI: | 10.1111/imj.14712 |
| Popis: | BACKGROUND: Evidence supporting dose modifications to reduce serious treatment-related adverse events of antineoplastic therapy is limited and frequently based on clinical trial protocols, which are not always generalisable to community patients. eviQ is an online resource with treatment protocols and recommendations for dose modification formulated by expert opinion and evidence-based review. Original recommended haematological thresholds to delay treatment were: neutrophil count |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text